Бессимптомная гиперурикемия и риск развития сердечно-сосудистых и почечных заболеваний

Бессимптомная гиперурикемия (ГУ) широко распространена в популяции и вносит существенный вклад в общий сердечно-сосудистый риск. Несмотря на активное изучение проблемы, до сих пор нет единых ответов на вопросы, касающиеся определения бессимптомной ГУ, ее влияния на риск развития и прогрессирования сердечно-сосудистых и почечных заболеваний. В обзоре суммированы основные сведения по данным вопросам, накопленные к настоящему времени.

1. Borghi C, Rosei EA, Bardin T, Dawson J, Dominiczak A, Kielstein JT et al. Serum uric acid and the risk of cardiovascular and renal disease: Journal of Hypertension. 2015;33(9):1729–41. DOI: 10.1097/HJH.0000000000000701

2. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(10):1953– 2041. DOI: 10.1097/HJH.0000000000001940

3. Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):149-218. DOI: 10.15829/1560-4071-2020-3-3786

4. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis & Rheumatism. 2011;63(10):3136–41. DOI: 10.1002/art.30520

5. Mount DB. Asymptomatic hyperuricemia. Av. at: https://www.uptodate.com/contents/asymptomatic-hyperuricemia.

6. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions: Current Opinion in Rheumatology. 2014;26(2):186–91. DOI: 10.1097/BOR.0000000000000028

7. Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution. Seminars in Arthritis and Rheumatism. 2017;46(4):457–64. DOI: 10.1016/j.semarthrit.2016.07.015

8. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. American Journal of Kidney Diseases. 2018;71(6):851–65. DOI: 10.1053/j.ajkd.2017.12.009

9. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. Current Hypertension Reports. 2016;18(10):74. DOI: 10.1007/s11906-016-0684-z

10. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. BMC Nephrology. 2014;15(1):122. DOI: 10.1186/1471-2369-15-122

11. Richette P, Doherty M, Pascual E, Barskova V, Becce F, CastañedaSanabria J et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases. 2017;76(1):29–42. DOI: 10.1136/annrheumdis-2016-209707

12. Borghi C, Tykarski A, Widecka K, Filipiak KJ, Domienik-Karłowicz J, Kostka-Jeziorny K et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiology Journal. 2018;25(5):545–63. DOI: 10.5603/CJ.2018.0116

13. Шальнова С.А., Деев А.Д., Артамонова Г.В., Дупляков Д.В., Ефанов А.Ю., Жернакова Ю.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕРФ). Рациональная фармакотерапия в кардиологии. 2014;10(2):153- 9. DOI: 10.20996/1819-6446-2014-10-2-153-159

14. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews Rheumatology. 2020;16(7):380–90. DOI: 10.1038/s41584-020-0441-1

15. Smith E, March L. Global Prevalence of Hyperuricemia: A Systematic Review of Population-Based Epidemiological Studies. Abstract 2236. Arthritis Rheumatology. 2015;67(Suppl 10). Av. at: https://acrabstracts.org/abstract/global-prevalence-of-hyperuricemia-a-systematic-review-of-population-based-epidemiological-studies/.

16. Conen D, Wietlisbach V, Bovet P, Shamlaye C, Riesen W, Paccaud F et al. Prevalence of hyperuricemia and relation of serum uric acid with cardiovascular risk factors in a developing country. BMC Public Health. 2004;4(1):9. DOI: 10.1186/1471-2458-4-9

17. Qiu L, Cheng X, Wu J, Liu J, Xu T, Ding H et al. Prevalence of hyperuricemia and its related risk factors in healthy adults from Northern and Northeastern Chinese provinces. BMC Public Health. 2013;13(1):664. DOI: 10.1186/1471-2458-13-664

18. Johnson RJ, Sautin YY, Oliver WJ, Roncal C, Mu W, Gabriela Sanchez-Lozada L et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society? Journal of Comparative Physiology B. 2009;179(1):67–76. DOI: 10.1007/s00360-008-0291-7

19. Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective – A review. Journal of Advanced Research. 2017;8(5):495–511. DOI: 10.1016/j.jare.2017.04.008

20. Ichida K, Matsuo H, Takada T, Nakayama A, Murakami K, Shimizu T et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nature Communications. 2012;3(1):764. DOI: 10.1038/ncomms1756

21. Park B, Park E, Cho S, Kim Y, Lee H, Min J et al. The Association Between Fetal and Postnatal Growth Status and Serum Levels of Uric Acid in Children at 3 Years of Age. American Journal of Hypertension. 2009;22(4):403–8. DOI: 10.1038/ajh.2009.12

22. Washburn LK, Nixon PA, Russell GB, Snively BM, O’Shea TM. Preterm Birth Is Associated with Higher Uric Acid Levels in Adolescents. The Journal of Pediatrics. 2015;167(1):76–80. DOI: 10.1016/j.jpeds.2015.03.043

23. Ильина А.Е., Барскова В.Г., Насонов Е.Л. Бессимптомная гиперурикемия - польза или вред? Русский Медицинский Журнал. 2008;16(24):1619-21

24. Lin C, Zhang P, Xue Y, Huang Y, Ji K. Link of renal microcirculatory dysfunction to increased coronary microcirculatory resistance in hypertensive patients. Cardiology Journal. 2017;24(6):623–32. DOI: 10.5603/CJ.a2017.0074

25. Fabbrini E, Serafini M, Colic Baric I, Hazen SL, Klein S. Effect of Plasma Uric Acid on Antioxidant Capacity, Oxidative Stress, and Insulin Sensitivity in Obese Subjects. Diabetes. 2014;63(3):976–81. DOI: 10.2337/db13-1396

26. George J, Carr E, Davies J, Belch JJF, Struthers A. High-Dose Allopurinol Improves Endothelial Function by Profoundly Reducing Vascular Oxidative Stress and Not by Lowering Uric Acid. Circulation. 2006;114(23):2508–16. DOI: 10.1161/CIRCULATIONAHA.106.651117

27. Chaudhary K, Malhotra K, Sowers J, Aroor A. Uric Acid – Key Ingredient in the Recipe for Cardiorenal Metabolic Syndrome. Cardiorenal Medicine. 2013;3(3):208–20. DOI: 10.1159/000355405

28. Jalal DI. Hyperuricemia, the kidneys, and the spectrum of associated diseases: a narrative review. Current Medical Research and Opinion. 2016;32(11):1863–9. DOI: 10.1080/03007995.2016.1218840

29. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мильто А.С. Мочевая кислота – ключевой компонент “кардиоренометаболического континуума”. Кардиоваскулярная терапия и профилактика. 2008;7(4):95-100

30. Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Караулова Ю.Л. Мочевая кислота - маркер и/или новый фактор риска развития сердечно-сосудистых осложнений? Клиническая фармакология и терапия. 2002;11(3):32-9

31. Feig DI, Kang D-H, Johnson RJ. Uric Acid and Cardiovascular Risk. New England Journal of Medicine. 2008;359(17):1811–21. DOI: 10.1056/NEJMra0800885

32. Cicero AFG, Salvi P, D’Addato S, Rosticci M, Borghi C. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. Journal of Hypertension. 2014;32(1):57–64. DOI: 10.1097/HJH.0b013e328365b916

33. Loeffler LF, Navas-Acien A, Brady TM, Miller ER, Fadrowski JJ. Uric Acid Level and Elevated Blood Pressure in US Adolescents: National Health and Nutrition Examination Survey, 1999–2006. Hypertension. 2012;59(4):811–7. DOI: 10.1161/HYPERTENSIONAHA.111.183244

34. Бритов А.Н., Елисеев Н.А., Деев А.Д., Балкаров И.М. Взаимосвязь артериальной гипертонии, обменных нарушений и уратной нефропатии. Терапевтический архив. 2006;78(5):41-5

35. Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study. International Journal of Cardiology. 2016;218:83–8. DOI: 10.1016/j.ijcard.2016.05.044

36. Cicero AFG, Rosticci M, Fogacci F, Grandi E, D’Addato S, Borghi C. High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects. European Journal of Internal Medicine. 2017;37:38–42. DOI: 10.1016/j.ejim.2016.07.026

37. Bombelli M, Ronchi I, Volpe M, Facchetti R, Carugo S, Dell’Oro R et al. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. Journal of Hypertension. 2014;32(6):1237–44. DOI: 10.1097/HJH.0000000000000161

38. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: A systematic review and meta-analysis: Risk of Incident Hypertension Associated With Hyperuricemia. Arthritis Care & Research. 2011;63(1):102–10. DOI: 10.1002/acr.20344

39. Wang J, Qin T, Chen J, Li Y, Wang L, Huang H et al. Hyperuricemia and Risk of Incident Hypertension: A Systematic Review and MetaAnalysis of Observational Studies. PLoS ONE. 2014;9(12):e114259. DOI: 10.1371/journal.pone.0114259

40. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and Incidence of Hypertension Among Men Without Metabolic Syndrome. Hypertension. 2007;49(2):298–303. DOI: 10.1161/01.HYP.0000254480.64564.b6

41. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, Gaziano M et al. Uric Acid and the Development of Hypertension: The Normative Aging Study. Hypertension. 2006;48(6):1031–6. DOI: 10.1161/01.HYP.0000248752.08807.4c

42. Forman JP, Choi H, Curhan GC. Uric Acid and Insulin Sensitivity and Risk of Incident Hypertension. Archives of Internal Medicine. 2009;169(2):155–62. DOI: 10.1001/archinternmed.2008.521

43. Zhang W, Sun K, Yang Y, Zhang H, Hu FB, Hui R. Plasma Uric Acid and Hypertension in a Chinese Community: Prospective Study and Metaanalysis. Clinical Chemistry. 2009;55(11):2026–34. DOI: 10.1373/clinchem.2009.124891

44. Shankar A, Klein R, Klein BEK, Nieto FJ. The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. Journal of Human Hypertension. 2006;20(12):937–45. DOI: 10.1038/sj.jhh.1002095

45. Sundström J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of Serum Uric Acid to Longitudinal Blood Pressure Tracking and Hypertension Incidence. Hypertension. 2005;45(1):28–33. DOI: 10.1161/01.HYP.0000150784.92944.9a

46. Gomez-Marcos MA, Recio-Rodriguez JI, Patino-Alonso MC, AgudoConde C, Rodriguez-Sanchez E, Gomez-Sanchez L et al. Relationship Between Uric Acid and Vascular Structure and Function in Hypertensive Patients and Sex-Related Differences. American Journal of Hypertension. 2013;26(5):599–607. DOI: 10.1093/ajh/hps097

47. Mehta T, Nuccio E, McFann K, Madero M, Sarnak MJ, Jalal D. Association of Uric Acid With Vascular Stiffness in the Framingham Heart Study. American Journal of Hypertension. 2015;28(7):877–83. DOI: 10.1093/ajh/hpu253

48. Liu H, Liu J, Zhao H, Zhou Y, Li L, Wang H et al. Relationship between Serum Uric Acid and Vascular Function and Structure Markers and Gender Difference in a Real-World Population of China-From Beijing Vascular Disease Patients Evaluation Study (BEST) Study. Journal of Atherosclerosis and Thrombosis. 2018;25(3):254–61. DOI: 10.5551/jat.39685

49. Chao T-F, Hung C-L, Chen S-J, Wang K-L, Chen T-J, Lin Y-J et al. The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. International Journal of Cardiology. 2013;168(4):4027–32. DOI: 10.1016/j.ijcard.2013.06.067

50. Cuspidi C, Facchetti R, Bombelli M, Sala C, Tadic M, Grassi G et al. Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. American Journal of Hypertension. 2017;30(3):279–85. DOI: 10.1093/ajh/hpw159

51. Кобалава Ж.Д., Толкачева В.В. Мочевая кислота – независимый предиктор сердечно-сосудистых событий. Урикозурический потенциал лозартана. Клиническая фармакология и терапия. 2011;20(3):9-17

52. Johnson RJ, Kang D-H, Feig D, Kivlighn S, Kanellis J, Watanabe S et al. Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease? Hypertension. 2003;41(6):1183–90. DOI: 10.1161/01.HYP.0000069700.62727.C5

53. Ioachimescu AG, Brennan DM, Hoar BM, Hazen SL, Hoogwerf BJ. Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: A preventive cardiology information system (PreCIS) database cohort study. Arthritis & Rheumatism. 2008;58(2):623–30. DOI: 10.1002/art.23121

54. Kuo C-F, See L-C, Yu K-H, Chou I-J, Chiou M-J, Luo S-F. Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality. Rheumatology. 2013;52(1):127–34. DOI: 10.1093/rheumatology/kes223

55. Tseng W, Chen Y, Ou S, Shih C, Tarng D, for the Taiwan Geriatric Kidney Disease (TGKD) Research Group et al. U‐Shaped Association Between Serum Uric Acid Levels With Cardiovascular and All‐ Cause Mortality in the Elderly: The Role of Malnourishment. Journal of the American Heart Association. 2018;7(4):e007523. DOI: 10.1161/JAHA.117.007523

56. Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K et al. Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy. European Heart Journal. 2019;40(22):1778–86. DOI: 10.1093/eurheartj/ehz119

57. Bos MJ, Koudstaal PJ, Hofman A, Witteman JCM, Breteler MMB. Uric Acid Is a Risk Factor for Myocardial Infarction and Stroke: The Rotterdam Study. Stroke. 2006;37(6):1503–7. DOI: 10.1161/01.STR.0000221716.55088.d4

58. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417 734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS): Uric acid and risk of AMI, stroke and CHF. Journal of Internal Medicine. 2009;266(6):558–70. DOI: 10.1111/j.1365- 2796.2009.02133.x

59. Casiglia E, Tikhonoff V, Virdis A, Masi S, Barbagallo CM, Bombelli M et al. Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values. Journal of Hypertension. 2020;38(3):412–9. DOI: 10.1097/HJH.0000000000002287

60. Crosta F, Occhiuzzi U, Passalacqua G, Occhiuzzi E, Cimini A, Grassi D et al. Association Between the Serum Uric Acid Levels and Lacunar Infarcts in the Elderly. Journal of Molecular Neuroscience. 2018;65(3):385–90. DOI: 10.1007/s12031-018-1096-0

61. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, Allopurinol Use, and Heart Failure Outcomes. Archives of Internal Medicine. 2010;170(15):1358–64. DOI: 10.1001/archinternmed.2010.198

62. Синютина Е.А., Карлуш П.Ж, Александрия Л.Г., Моисеев В.С. Связь гиперурикемии с клинико-гемодинамическими и лабораторными показателями у больных хронической сердечной недостаточностью. Клиническая фармакология и терапия. 2011;20(4):41-5

63. Моисеев В.С, Терещенко С.Н., Дроздов В.Н., Левчук Н.Н. Уровень мочевой кислоты в крови больных с постинфарктной сердечной недостаточностью. Терапевтический архив. 2000;72(9):57-60

64. Lv Q, Meng X-F, He F-F, Chen S, Su H, Xiong J et al. High Serum Uric Acid and Increased Risk of Type 2 Diabetes: A Systemic Review and Meta-Analysis of Prospective Cohort Studies. PLoS ONE. 2013;8(2):e56864. DOI: 10.1371/journal.pone.0056864

65. Yu TY, Jee JH, Bae JC, Jin S-M, Baek J-H, Lee M-K et al. Serum uric acid: A strong and independent predictor of metabolic syndrome after adjusting for body composition. Metabolism. 2016;65(4):432–40. DOI: 10.1016/j.metabol.2015.11.003

66. Culleton BF, Larson MG, Kannel WB, Levy D. Serum Uric Acid and Risk for Cardiovascular Disease and Death: The Framingham Heart Study. Annals of Internal Medicine. 1999;131(1):7–13. DOI: 10.7326/0003-4819-131-1-199907060-00003

67. Stack AG, Hanley A, Casserly LF, Cronin CJ, Abdalla AA, Kiernan TJ et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM: An International Journal of Medicine. 2013;106(7):647–58. DOI: 10.1093/qjmed/hct083

68. Yang Q, Köttgen A, Dehghan A, Smith AV, Glazer NL, Chen M-H et al. Multiple Genetic Loci Influence Serum Urate Levels and Their Relationship With Gout and Cardiovascular Disease Risk Factors. Circulation: Cardiovascular Genetics. 2010;3(6):523–30. DOI: 10.1161/CIRCGENETICS.109.934455

69. Pfister R, Barnes D, Luben R, Forouhi NG, Bochud M, Khaw K-T et al. No evidence for a causal link between uric acid and type 2 diabetes: a Mendelian randomisation approach. Diabetologia. 2011;54(10):2561–9. DOI: 10.1007/s00125-011-2235-0

70. Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF et al. Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. Journal of the American College of Cardiology. 2016;67(4):407–16. DOI: 10.1016/j.jacc.2015.10.086

71. Kleber ME, Delgado G, Grammer TB, Silbernagel G, Huang J, Krämer BK et al. Uric Acid and Cardiovascular Events: A Mendelian Randomization Study. Journal of the American Society of Nephrology. 2015;26(11):2831–8. DOI: 10.1681/ASN.2014070660

72. Yan D, Wang J, Jiang F, Zhang R, Wang T, Wang S et al. A causal relationship between uric acid and diabetic macrovascular disease in Chinese type 2 diabetes patients: A Mendelian randomization analysis. International Journal of Cardiology. 2016;214:194–9. DOI: 10.1016/j.ijcard.2016.03.206

73. Zhao G, Huang L, Song M, Song Y. Baseline serum uric acid level as a predictor of cardiovascular disease related mortality and all-cause mortality: A meta-analysis of prospective studies. Atherosclerosis. 2013;231(1):61–8. DOI: 10.1016/j.atherosclerosis.2013.08.023

74. Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C et al. Serum Uric Acid Levels and Risk of Metabolic Syndrome: A Dose-Response Meta-Analysis of Prospective Studies. The Journal of Clinical Endocrinology & Metabolism. 2015;100(11):4198–207. DOI: 10.1210/jc.2015-2527

75. Wang R, Song Y, Yan Y, Ding Z. Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis. 2016;254:193–9. DOI: 10.1016/j.atherosclerosis.2016.10.006

76. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Association of kidney disease with prevalent gout in the United States in 1988–1994 and 2007–2010. Seminars in Arthritis and Rheumatism. 2013;42(6):551– 61. DOI: 10.1016/j.semarthrit.2012.09.009

77. Jing J, Kielstein JT, Schultheiss UT, Sitter T, Titze SI, Schaeffner ES et al. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrology Dialysis Transplantation. 2015;30(4):613–21. DOI: 10.1093/ndt/gfu352

78. Bonino B, Leoncini G, Russo E, Pontremoli R, Viazzi F. Uric acid in CKD: has the jury come to the verdict? Journal of Nephrology. 2020;33(4):715–24. DOI: 10.1007/s40620-020-00702-7

79. Domrongkitchaiporn S, Sritara P, Kitiyakara C, Stitchantrakul W, Krittaphol V, Lolekha P et al. Risk Factors for Development of Decreased Kidney Function in a Southeast Asian Population: A 12-Year Cohort Study. Journal of the American Society of Nephrology. 2005;16(3):791–9. DOI: 10.1681/ASN.2004030208

80. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated Uric Acid Increases the Risk for Kidney Disease. Journal of the American Society of Nephrology. 2008;19(12):2407–13. DOI: 10.1681/ASN.2008010080

81. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric Acid and Incident Kidney Disease in the Community. Journal of the American Society of Nephrology. 2008;19(6):1204–11. DOI: 10.1681/ASN.2007101075

82. Hsu C, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk Factors for End-Stage Renal Disease: 25-Year Follow-up. Archives of Internal Medicine. 2009;169(4):342–50. DOI: 10.1001/archinternmed.2008.605

83. Yamada T, Fukatsu M, Wada T, Suzuki S, Joh T. Elevated Serum Uric Acid Predicts Chronic Kidney Disease. The American Journal of the Medical Sciences. 2011;342(6):461–6. DOI: 10.1097/MAJ.0b013e318218bd89

84. Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrology Dialysis Transplantation. 2012;27(5):1831–5. DOI: 10.1093/ndt/gfr530

85. Takae K, Nagata M, Hata J, Mukai N, Hirakawa Y, Yoshida D et al. Serum Uric Acid as a Risk Factor for Chronic Kidney Disease in a Japanese Community – The Hisayama Study. Circulation Journal. 2016;80(8):1857–62. DOI: 10.1253/circj.CJ-16-0030

86. Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I et al. Serum Uric Acid Levels and Incident Chronic Kidney Disease in Patients With Type 2 Diabetes and Preserved Kidney Function. Diabetes Care. 2012;35(1):99–104. DOI: 10.2337/dc11-1346

87. De Cosmo S, Viazzi F, Pacilli A, Giorda C, Ceriello A, Gentile S et al. Serum Uric Acid and Risk of CKD in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology. 2015;10(11):1921–9. DOI: 10.2215/CJN.03140315

88. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW et al. Uric Acid and Long-term Outcomes in CKD. American Journal of Kidney Diseases. 2009;53(5):796–803. DOI: 10.1053/j.ajkd.2008.12.021

89. Nacak H, van Diepen M, Qureshi AR, Carrero JJ, Stijnen T, Dekker FW et al. Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease. Nephrology Dialysis Transplantation. 2015;30(12):2039–45. DOI: 10.1093/ndt/gfv225

90. Tsai C-W, Lin S-Y, Kuo C-C, Huang C-C. Serum Uric Acid and Progression of Kidney Disease: A Longitudinal Analysis and Mini-Review. PLOS ONE. 2017;12(1):e0170393. DOI: 10.1371/journal. pone.0170393

91. Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T et al. Targeting Uric Acid and the Inhibition of Progression to EndStage Renal Disease – A Propensity Score Analysis. PLOS ONE. 2015;10(12):e0145506. DOI: 10.1371/journal.pone.0145506

92. Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. American Journal of Kidney Diseases. 2018;71(3):362–70. DOI: 10.1053/j.ajkd.2017.08.017

93. Kanda E, Muneyuki T, Kanno Y, Suwa K, Nakajima K. Uric Acid Level Has a U-Shaped Association with Loss of Kidney Function in Healthy People: A Prospective Cohort Study. PLOS ONE. 2015;10(2):e0118031. DOI: 10.1371/journal.pone.0118031

94. Xia X, Luo Q, Li B, Lin Z, Yu X, Huang F. Serum uric acid and mortality in chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2016;65(9):1326–41. DOI: 10.1016/j.metabol.2016.05.009

95. Luo Q, Xia X, Li B, Lin Z, Yu X, Huang F. Serum uric acid and cardiovascular mortality in chronic kidney disease: a meta-analysis. BMC Nephrology. 2019;20(1):18. DOI: 10.1186/s12882-018-1143-7